Jeryl L. Hilleman
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Truist Securities raises SI-BONE price target to $25. Truist Securities kept its existing rating on SI‑BONE and lifted its price target to $25. The new target sits near the midpoint of the nine‑analyst consensus range of $20 to $32, and slightly above the current 52‑week high of $21.89. This adjustment suggests the firm sees further upside potential for the company.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
NovoCure Gains Japan Approval for Optune Pax in Pancreatic Cancer. NovoCure received regulatory approval in Japan for Optune Pax to treat pancreatic cancer. This development is significant because it expands the potential market for the company's device. Analyst notes suggest this approval may shift the investment thesis by highlighting the firm's cash generation capabilities.
Transaction History
| OMDA | ▲ Buy | Grant | 1,214 | $0 | 10/5/2026 | View on chart |
| OMDA | ▲ Buy | Grant | 1,299 | $0 | 7/5/2026 | View on chart |
| OMDA | ▲ Buy | Grant | 10,882 | $0 | 6/16/2026 | View on chart |
| SIBN | ▲ Buy | Grant | 10,957 | $0 | 6/4/2026 | View on chart |
| NVCR | ▲ Buy | Grant | 11,610 | $0 | 6/3/2026 | View on chart |
| NVCR | ▼ Sell | Open Market | 2,945 | $46K | 6/2/2026 | View on chart |
| OMDA | ▲ Buy | Grant | 1,544 | $0 | 4/5/2026 | View on chart |
| OMDA | ▲ Buy | Grant | 1,601 | $0 | 1/5/2026 | View on chart |
| OMDA | ▲ Buy | Grant | 1,126 | $0 | 10/5/2025 | View on chart |
| OMDA | ▲ Buy | Grant | 376 | $0 | 7/5/2025 | View on chart |
| OMDA | ▲ Buy | Grant | 9,736 | $0 | 6/5/2025 | View on chart |
| SIBN | ▲ Buy | Grant | 8,675 | $0 | 6/5/2025 | View on chart |
| NVCR | ▲ Buy | Grant | 11,215 | $0 | 6/4/2025 | View on chart |
| NVCR | ▼ Sell | Open Market | 999 | $17K | 6/3/2025 | View on chart |
| SIBN | ▲ Buy | Grant | 8,791 | $0 | 6/26/2024 | View on chart |
| NVCR | ▲ Buy | Grant | 4,053 | $0 | 6/5/2024 | View on chart |
| SIBN | ▼ Sell | Open Market | 2,081 | $58K | 6/20/2023 | View on chart |
| SIBN | ▼ Sell | Open Market | 2,081 | $60K | 6/15/2023 | View on chart |
| SIBN | ▲ Buy | Grant | 4,866 | $0 | 6/9/2023 | View on chart |
| SIBN | ▲ Buy | Grant | 8,324 | $0 | 6/16/2022 | View on chart |
| SIBN | ▼ Sell | Open Market | 1,924 | $27K | 6/13/2022 | View on chart |
| NVCR | ▼ Sell | Open Market | 407 | $28K | 6/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Omada Health Sets Q3 2026 Earnings Call, Investors Question Valuation
Omada Health will report its third quarter 2026 results on November 5 and host a conference call. Recent commentary highlights the company’s growth but raises concerns about its competitive moat and long‑term price targets. Analysts note a high trailing P/E of 260.2 and a wide target range of $22.00 to $35.00. The upcoming call may clarify how the firm plans to address these valuation questions.
Omada Health Sets Q3 2026 Earnings Call, Investors Question Valuation. Omada Health will report its third quarter 2026 results on November 5 and host a conference call. Recent commentary highlights the company’s growth but raises concerns about its competitive moat and long‑term price targets. Analysts note a high trailing P/E of 260.2 and a wide target range of $22.00 to $35.00. The upcoming call may clarify how the firm plans to address these valuation questions.